Physician profile
Anjuli Jindal
NPI 1043493372
$2,402.96
in general payments reported to CMS, 2019-2025
12 companies · $904 in 2025
The $904 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $36.26 · 2021: $110 · 2022: $358 · 2023: $158 · 2024: $503 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488 · Education: $78.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.56 |
| Education | $78.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $657.18 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $390.45 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $328.41 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $219.00 | 2022-2025 | Caplyta |
| Alkermes, INC. | $210.36 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $193.44 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $184.96 | 2024-2025 | Cobenfy |
| Gilead Sciences, INC. | $116.10 | 2024 | Epclusa |
| Teva Pharmaceuticals USA, INC. | $41.38 | 2025 | Uzedy |
| Axsome Therapeutics, INC. | $31.81 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $17.99 | 2025 | Fanapt |
| Noven Therapeutics, LLC | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjuli Jindal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.